Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sarepta Therapeutics Q3 2026 Results: Net Loss of $28.5M, Loss Narrows

Sarepta Therapeutics reported a net income of $297.6 million for the first nine months of 2026, a significant turnaround from a $301.2 million loss in the prior year period. Total revenues for the nine months reached $1.51 billion, driven by $983.0 million in net product sales and $530.4 million from collaboration and other revenue.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue381.4399.4
Profit before tax-25.8-64.7
Net income-28.5-50.6
EPS (diluted, $ a share)$-0.27$-0.50

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-4.5%
Operating margin-2.4%
Source

10-Q filed with the SEC, NASDAQ: SRPT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sarepta Therapeutics, Inc.: key numbers

Share price
$15.13Close, Nov 16
Market cap
$1.62B
Shares outstanding
107.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sarepta Therapeutics, Inc.

All →
4:14 PM ET 8-K
Financial Results

Sarepta Therapeutics Financial Results

Sarepta Therapeutics reported Q3 2026 financial results with net product revenues of $323.8 million, driven by its PMO franchise and ELEVIDYS. The company achieved positive cash flow and non-GAAP operating income of $22.9 million while preparing for Phase 3 development in its DM1 and FSHD programs.

Term
Q3 2026

“After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.”

Michael Severino, M.D., chief executive officer, Sarepta

“This quarter, we saw continued strength in our commercial execution. Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve.”

Michael Severino, M.D., chief executive officer, Sarepta
4:14 PM ET 8-K
Court & Legal Update

Sarepta Therapeutics Court & Legal Update

Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, the University of Pennsylvania, and Catalent to resolve pending patent infringement litigation regarding the '274 and '617 patents. Sarepta will pay a lump sum of $39.0 million to REGENXBIO in exchange for a release of claims and a covenant not to sue regarding Sarepta's gene therapy products using the AAVrh74-based capsid, including ELEVIDYS. The settlement resolves all pending litigations with prejudice and includes no admission of liability.

Counterparty
REGENXBIO Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.